What is sarilumab?
Sarilumab is a monoclonal antibody approved for the treatment of polymyalgia rheumatica (PMR).
How does sarilumab work?
Sarilumab blocks the action of IL-6 – an immune system protein that drives inflammation. Tocilizumab is another drug that blocks IL-6 and is used in the treatment of Giant Cell Arteritis (GCA).
How is sarilumab given?
Sarilumab is given as a self-administered injection at a dose of 200 mg every 2 weeks.
Side effects:
We pay particular attention to liver function tests, lipids, and blood counts when using sarilumab.
All immunosuppressants require regular monitoring in the form of blood tests, in-person assessments, and vigilance for signs of infection.
Receive the Latest News from Johns Hopkins Rheumatology
Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.
